Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

Inclusion Criteria: 1. Male and female adults aged 19 years and older 2. Patients with solid tumors as below (1) histologically or cytologically confirmed solid tumors (2) 4 - 12 weeks of last adjuvant therapy after radical operations and adjuvant therapy 3. Life expectancy 6 months 4. Eastern Cooperative Oncology Group perfornace status (ECOG PS) 0-1 Exclusion Criteria: 1. History of leptomeningeal carcinomatosis or spinal cord compression 2. History of peritoneal carninomatosis 3. Hemoglobine less than 9.0g/dL 4. Absolute Neutrophil Count (ANC) less than 1.5x10\^3/mm\^3 5. Platelet count less than 75x10\^9/L 6. Total bilitbinn grater than 1.5 times te upper limit of normal 7. Alanine amino transferase (ALT) greater than 3 times the upper limit of normal 8. Alanine phospatase (ALP) greater than 2.5 times the upper limit of normal 9. Uncontrolled hypertension 10. Intensive insuline therapy 11. Active infectious disease 12. Patients with hypersensitivity history or allergy to investigational product 13. Pregmant of lactating woman 14. Patients who have participated in another clinical trials witin 30 days before the start of this clinical trial 15. Patients judged to be inappropriate for this study by the investigator with other reasons